tirzepatide denver co Weight Loss Injections & Clinics Near You Tirzepatide Oral | Starts at

is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the global weight-loss market thats expected to touch $100 billion by 2030.

Read more here about the lawsuit.

It hits three receptors simultaneously: GLP-1, GIP, and glucagon

The combination of GLP-1 and GIP agonists improves glycemic control and promotes weight loss

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

Stay informed on availability and make empowered decisions for your health today.